Chong Kun Dang Pharmaceutical Corp. is a Korean pharmaceutical company operating for over a decade (currently in its 12th fiscal year as of 2024). [TRANSLATION NOTE] Based on the company name structure typical of Korean pharma firms, this is likely a diversified pharmaceutical manufacturer with prescription drugs, over-the-counter medications, and potentially biotech operations, though specific segment details are not provided in the financial data available.
The company is experiencing significant operational pressure. Revenue declined 5.0% year-over-year to KRW 1,586 billion in 2024 from KRW 1,669 billion in 2023, reversing earlier growth momentum (2022: KRW 1,488 billion).
More concerning is the sharp margin contraction. Operating profit collapsed 59.7% to KRW 99.5 billion in 2024 from KRW 246.6 billion in 2023, driving the operating margin down from 14.8% to just 6.3%. Despite this operational deterioration, net income declined less severely (-47.8% to KRW 111.4 billion), suggesting some support from non-operating items.
The balance sheet shows moderate leverage with total debt of KRW 562.4 billion against total equity of KRW 896.4 billion (debt-to-equity ratio of 0.63) as of year-end 2024. Notably, non-current liabilities increased sharply by 157% year-over-year to KRW 193.8 billion, indicating new long-term financing. Total assets grew 4.0% to KRW 1,459 billion, with retained earnings strengthening to KRW 671.4 billion despite the challenging year.
[TRANSLATION NOTE] The filing data provided does not include ownership structure details or foreign ownership percentages. This information would typically be found in separate disclosure documents (주주현황) not included in this dataset.
1. Severe Margin Erosion: The 60% operating profit decline on only modest revenue contraction suggests either significant pricing pressure in core products, unsustainable cost inflation, or major one-time expenses that may recur. Without segment detail, the source of this pressure remains opaque but critical.
2. Revenue Reversal: After achieving KRW 1,669 billion in sales (2023), the company failed to maintain growth trajectory, raising questions about competitive positioning, patent expirations on key products, or market share losses that could persist into 2025.
Chong Kun Dang presents a classic value-versus-risk dilemma with a KRW 1.18 trillion market cap trading below 1.3x book value, but investors must determine whether 2024's margin collapse represents a temporary shock or structural deterioration requiring fundamental business repositioning.
⚠️ This profile is AI-generated from DART filings. Quantitative data is reliable. Qualitative summaries should be verified against original Korean filings for investment decisions.